Abstract: Ca 2+ /calmodulin-dependent protein kinase II (CaM-KII) activation through autophosphorylation at threonine 286 was involved in the modulation of neuronal excitability and neurotransmission. Both propofol and ketamine may affect the intracellular Ca 2+ levels through N-methyl-D-aspartate receptors or voltage-dependent Ca 2+ channels, but they have different mechanisms in general anesthesia. The purpose of this study was to investigate the effects of propofol and ketamine on CaMKII total protein and phosphorylation (p-CaMKII) levels in the brain of rats. We found that both propofol and ketamine could induce a decrease of p-CaMKII, not CaMKII total protein, in an anesthetic depth-dependent manner, whereas only ketamine caused a dose (50, 100, and 150 mg/kg)-dependent depression of p-CaMKII in hippocampus and frontal cortex of rats after intraperitoneal injections for 30 minutes. The significant depressions of p-CaMKII started at 5 minutes both in hippocampus and frontal cortex of rats after 100 mg/kg propofol treatment, whereas 100 mg/kg ketamine-induced significant depression of p-CaMKII initiated at 30 minutes in hippocampus and 5 minutes (no reduction observed at 15 min) in frontal cortex of rats. The maximum reduction of p-CaMKII with both drugs was at 60 minutes, and then restored to control level at 240 minutes. In addition, we confirmed the depression of p-CaMKII in hippocampus and frontal cortex of rats after 100 mg/kg of propofol or ketamine treatment for 60 minutes by using immunostaining. These results suggested that decreased p-CaMKII levels correlate with anesthetic depths achieved by propofol and ketamine, which may be related to the effects of propofol and ketamine on central nervous system function and their clinical effect.
A s a multifunctional serine/threonine protein kinase, Ca 2+ /calmodulin (CaM)-dependent protein kinase II (CaMKII) family, which consists of a, b, g, and d isoforms, is highly concentrated in neuronal tissues and involved in a variety of Ca 2+ -mediated cellular processes, such as biosynthesis, secretions of neurotransmitter and hormone, axonal transport, receptor function, regulation of gene expression, and neuronal plasticity. [1] [2] [3] CaMKII a and b isoforms are predominantly expressed in the brain, whereas the CaMKII g and d isoforms are expressed in all tissues. CaMKII contains a catalytic and regulatory domain (including an autoinhibitory and CaM binding site). In the central nervous system (CNS), postsynaptic Ca 2+ influx triggers rapid autophosphorylation (stable activation) in a Ca 2+ /CaM-dependent manner at threonine 286 of CaMKII a (p-Thr 286 CaMKII a) and threonine 287 for CaMKII b (p-Thr 287 CaMKII b) in the autoinhibitory domain. [4] [5] [6] The elucidation of the biochemical properties of CaMKII has provided evidence that brief intracellular Ca 2+ ([Ca 2+ ] I ) signals can activate the kinase and stimulate an autophosphorylation reaction, resulting in the generation of long-lasting, Ca 2+ -independent autonomous activity. 7, 8 The increase of [Ca 2+ ] i induced by extracellular Ca 2+ influx via ionotropic N-methyl-D-aspartate (NMDA) receptors, voltagedependent calcium channels (VDCCs), and Ca 2+ release from intracellular Ca 2+ store is the major trigger for the direct and indirect activation of CaMKII.
Ketamine (phenyl-cyclohexyl-piperidine) and propofol (2,6-diisopropylphenol) are established nonbarbiturate anesthetic agents, commonly used in the clinical practices. Ketamine is a noncompetitive NMDA receptor antagonist; propofol was shown to exhibit properties of NMDA receptor antagonist and g-aminobutyric acid A receptor agonist and in regulating the voltage-sensitive Ca 2+ channels. 9 Both propofol and ketamine may affect the [Ca 2+ ] i levels through NMDA receptors or VDCCs. One of the primary mechanisms by which intracellular Ca 2+ regulates signal transduction is through activation of CaMKII. 10 Furthermore, both propofol and ketamine have different mechanisms in general anesthesia. Ketamine has been reported to cause undesirable psychologic reactions, such as vivid dreams and hallucinations. 11 Patients anesthetized with propofol report positive changes in mood like euphoria or elation upon recovery. 9 We wonder whether propofol and ketamine also affects CaMKII in CNS and may have different effects. The purpose of this study was to investigate the effects of propofol and ketamine on CaMKII total protein (T-CaMKII) and phosphorylation (p-CaMKII) levels in the brain of rats.
MATERIALS AND METHODS
The animal protocol was approved by the Animal Care and Use Committee of Capital Medical University and is consistent with the NIH Guide for the Care and Use of Laboratory Animals (NIH Publications No. 80-23). Male Sprague-Dawley rats weighing 220 to 250 g were initially housed in a temperature-controlled (21 to 241C) and light-controlled (12:12 h light-dark cycle) room with ad libitum access to food and water.
Propofol (Astra Zeneca, Italy) or ketamine (Jiangsu Hengrui Pharmaceutical Co Ltd, China) as indicated dosage was dissolved in 0.9% NaCl solution to a final volume of 4 mL. The rats received 4 mL propofol, ketamine, or equivalent volume of 0.9% NaCl solution injected intraperitoneally (IP). Rats were allowed to breathe spontaneously at a rate about 60 breathes/min and continuous pulse oximetry at the rat tail was used. Rectal temperature was maintained at 371C with an infrared heat lamp. Rats with arterial oxygen saturation (SpO 2 ) less than 90% would be excluded from this study. The anesthetic level was monitored by checking righting reflex, pinch withdrawal reflex, eyelid reflex, and spontaneous rapid whisking of the vibrissae. Rats that present righting reflex were said to be under ''subanesthesia'' and under ''light anesthesia'' when there were absence of righting reflex, and presence of pinch withdrawal reflex, eyelid reflex, and spontaneous whisking. The level of anesthesia was designated as ''deep anesthesia'' when all of the above were absent and no spontaneous whisking tremors were present. 12 To confirm the accuracy of intraperitoneal injection, laparotomy was performed after rats were killed.
Western Blot Analysis
The rats were killed by decapitation, and the hippocampus and frontal cortex regions were dissected, frozen in liquid nitrogen, and kept at À 701C. The tissue extracts were generated from the whole hippocampus and frontal cortex as in our previous reports. 13, 14 Each sample was thawed, homogenized at 41C in 200 mL buffer [50 mM Tris-Cl, pH 7.5, containing 2 mM dithiothreitol; 2 mM ethylene diamine tetraacetate; 2 mM ethylene glycol tetraacetic acid; 5 mg/mL each of leupeptin, aprotinin, pepstatin A, and chymostatin; 50 mM KF; 50 nM okadaic acid; 5 mM sodium pyrophosphate; 1 mM sodium vanidate; 1 mM dithiothreitol; and 2% sodium dodecyl sulfate (SDS)], sonicated to dissolve the tissue completely. Protein concentration was measured by using the BCA kit (Pierce Co).
SDS-polyacrylamide gel electrophoresis and Western blot analysis were carried out as previously reported. [15] [16] [17] Briefly, after separation of 40 mg of each sample by SDS-polyacrylamide gel electrophoresis (10% gel), proteins were transferred onto nitrocellulose (NC) membrane (Schleicher and Schell) at 41C, 400 mA for 3 hours. The transferred NC membrane was rinsed for 10 minutes in Tween tris-buffered salt solution (20 mM Tris, pH 7.5, containing 0.15 M NaCl, and 0.05% and then blocked with 10% nonfat milk for 1 hour. After washing for 3 times (each for 10 min) with Tween trisbuffered salt solution, the blocked NC membrane was incubated with primary rabbit polyclonal antibodies against p-CaMKII or T-CaMKII (Santa Cruz Biotechnology Inc) at a 1:1000 dilution for 3 hours. To check the slight variation in protein loading between samples, those membranes blotted with antibodies against p-CaMKII and T-CaMKII were reprobed with primary mouse monoclonal antibody against b-actin (Sigma-Aldrich Co) at a 1:1000 dilution for 2 hours as an internal control. Next, the membrane was incubated with horseradish peroxidase-conjugated goat antirabbit or mouse immunoglobulin G (Bio-Rad Co) at 1:4000 dilutions for 1 hour. Finally, the ECL plus Kit (Perkin-Elmer Life Science) was used to visualize the signals.
Immunostaining Study
For immunostaining, the propofol and ketaminetreated rats received 100 mg/kg propofol or ketamine injected IP for 60 minutes, whereas the saline control rats anesthetized with pentobarbital (50 mg/kg, IP). Then the rats were perfused transcardially with 0.9% NaCl, followed by 4% paraformaldehyde as in our previous reports. 13, 18 The brains were removed quickly, postfixed in 4% paraformaldehyde for 24 hours, and dehydrated in 20% and 30% sucrose solution. The tissue was frozen and sectioned on a sliding microtome at 50 mm thickness. Then the slices were placed in ice-cold 10 mM phosphate buffered saline (PBS). The slices were incubated with 0.03% H 2 O 2 for 10 minutes to block the activity of endogenous peroxidase and washed in phosphate buffered saline Triton X-100 (10 mM PBS, pH 7.4, containing 0.5% Triton X-100). To reduce nonspecific staining, sections were blocked with 10% bovine serum for 1 hour. The slices were incubated with primary rabbit polyclonal antibody against p-CaMKII at 1:400 dilutions for 12 hours at 41C. Alternative sections from each brain sample were incubated without the primary antibody as negative controls. The specimens were incubated in secondary antibody of biotinylated goat antirabbit immunoglobulin G (ZYMED Co) at 1:300 dilution for 2 hours and then incubated with streptavidin-conjugated horseradish peroxidase solution (Sigma-Aldrich Co) at 1:300 dilution for another 2 hours. Finally, the slices were washed extensively in PBS, and a solution containing H 2 O 2 (0.03%) and 3,3 0 -diaminobenzidine (60%) was added to visualize the slices. The images were captured by Leica microscope imaging system (Leica Co, Germany).
Statistical Analysis
Quantitative analysis for Western blot results was performed after scanning of the x-ray film with Quantitative-One software (Gel Doc-2000, Bio-Rad Co). To demonstrate T-CaMKII protein and p-CaMKII levels, FIGURE 1. Propofol and ketamine dose-dependent effects on CaMKII phosphorylation and protein expression levels in hippocampus and cortex of rats after intraperitoneal injections of propofol and ketamine for 30 minutes. A, Typical Western blot showed the changes in phosphorylated CaMKII at Threonine 286 (p-CaMKII) and total CaMKII (T-CaMKII) in rat hippocampus and cortex and B, quantitative analysis demonstrated a significant decrease in p-CaMKII both in hippocampus and cortex of rats after 30-minute propofol and ketamine treatments. *P<0.05 versus control (100%), n = 6 for each group. C indicates cortex; CaMKII, Ca 2+ /calmodulin-dependent protein kinase II; H, hippocampus; p-CaMKII, phosphorylated CaMKII; T-CaMKII, total CaMKII. 
RESULTS

Effects of Propofol and Ketamine on T-CaMKII and p-CaMKII Levels at Dose and Anesthetic Depth Dependency in Hippocampus and Cortex of Rats
We initially evaluated the effects of propofol and ketamine on T-CaMKII protein levels in hippocampus and cortex of rats. Forty-two rats were randomly assigned to 7 groups (n = 6 for each group), and received 50, 100, and 150 mg/kg of propofol or ketamine dissolved in 4 mL 0.9% NaCl solution by IP injection for 30 minutes. We found no significant changes in T-CaMKII in the hippocampus and frontal cortex from propofol or ketamine-treated rats when compared with that of control group (Fig. 1A , the quantitative data did not show). However, the p-CaMKII levels decreased both in hippocampus and frontal cortex of rats anesthetized with propofol and ketamine (Fig. 1A) , and the statistical significances (P<0.05) could be found at the dose of 50 (hippocampus: 45.2 ± 3.4%; cortex: 66.8 ± 6.5%), 100 (hippocampus: 32.2 ± 5.4%; cortex: 66.0 ± 10.0%), and 150 (hippocampus: 37.2 ± 5.7%; cortex: 58.1 ± 8.3%) of propofol, and 100 (hippocampus: 40.4 ± 5.3%; cortex: 38.2 ± 4.1%) and 150 (hippocampus: 33.4 ± 7.7%; cortex: 27.9 ± 6.7%) of ketamine when compared with control group (100%, Fig. 1B) .
Because of lacking dose-dependent changes in p-CaMKII levels under propofol anesthesia, we evaluated the correlation of anesthetic depths (subanesthesia, light and deep anesthesia) achieved by propofol and ketamine (30 min, Fig. 2 ) with p-CaMKII levels. The same animals were regrouped according to the determined depth of anesthesia, and this is plotted in Figure 3 . Propofol caused p-CaMKII levels decrease to 62.2 ± 2.7% (n = 10), 38.4 ± 2.4% (n = 10), and 20.7 ± 3.3% (n = 7) of the control level (100%, n = 6), and the values in ketamine groups were 85.6 ± 13.2% (n = 6), 43.6 ± 3.4% (n = 7), and 33.3 ± 4.6% (n = 6) in an anesthetic depth-dependent manner in hippocampus of rats (P<0.05, Figs. 3A, B) . In addition, the depression of p-CaMKII in cortex also showed similar changes in both propofol and ketamine groups (Figs. 3A, B) .
Effects of Propofol and Ketamine on T-CaMKII and p-CaMKII Levels at Time Dependency in Hippocampus and Cortex of Rats
As the treatment of propofol or ketamine at 100 mg/kg for 30 minutes could induce a significant decrease in p-CaMKII level, we further investigated the time course (5, 15, 30, 60, 120, and 240 min) of T-CaMKII and p-CaMKII in hippocampus and frontal cortex of rats anesthetized with 100 mg/kg of propofol or ketamine. The results showed that both propofol and ketamine could cause a significant decrease in p-CaMKII to 38.8 ± 14.1% and 98.8 ± 3.2% at 5 minutes, 46.2 ± 12.4% and 93.3 ± 1.9% at 15 minutes, and FIGURE 2. Changes in anesthetic depth of rats achieved by intraperitoneal injections of propofol and ketamine at different doses. A, propofol-induced anesthesia at 50 (n = 10), 100 (n = 10), and 150 mg/kg (n = 7) intraperitoneal injections for 30 minutes and B, ketamine-induced anesthesia at 50 (n = 6), 100 (n = 7), and 150 mg/kg (n = 6) intraperitoneal injections for 30 minutes. For propofol, there was no significant correlation between anesthetic depth and dosage. 1 indicates subanesthesia; 2, light anesthesia; 3, deep anesthesia.
46.9 ± 12.0% and 22.8 ± 4.4% at 30 minutes, reaching the maximum of 26.7 ± 8.5% and 11.1 ± 5.9% at 60 minutes, and then returning to the baseline of 105.6 ± 11.5% and 96.2 ± 1.6% at 240 minutes in the hippocampus of rats (Figs. 4A, B) . The similar changes of pCaMKII could also be observed in the frontal cortex of rats after propofol and ketamine IP injections (Figs. 5A, B) . However, there were no significant changes of T-CaMKII at all time points both in hippocampus and frontal cortex of rats after propofol or ketamine IP injection (Fig. 4A and Fig. 5A , the quantitative analysis of Western blot did not show). 
Immunostaining of Propofol and Ketamineinduced Depression of p-CaMKII in Hippocampus and Frontal Cortex of Rats
To further confirm the Western bolt results of propofol and ketamine-induced depression of p-CaMKII, the immunohistochemical analysis was carried out in the hippocampus and frontal cortex of rats after 100 mg/kg of propofol and ketamine IP injections for 60 minutes. The immunostaining results from control group showed that strong p-CaMKII immunoreactants distributed mainly in the pyramidal cells of the hippocampus (Fig. 6A , 116.7 ± 5.4 cells/field, n = 3) and frontal cortex (Fig. 6D,  93 .0 ± 2.3 cells/field, n = 3) of rats. Similar to the results of Western blot analysis, the marked decreases in FIGURE 4 . Time course of propofol and ketamine-induced inhibition on p-CaMKII levels in hippocampus of rats. A, Representative Western blot showed that p-CaMKII levels decreased in the hippocampus of rats at 5 to 120 minutes after propofol and ketamine treatments and B, the results of quantitative analysis demonstrated that both propofol and ketamine could cause a significant decrease in p-CaMKII in the hippocampus of rats at 5 to 120 and 30 to 120 minutes after treatment, respectively. *P<0.05 versus 0 minute (control) group, n = 8 for each group. p-CaMKII indicates phosphorylated Ca 2+ /calmodulindependent protein kinase II. 
DISCUSSION
The present study described the effects of propofol and ketamine on p-CaMKII and T-CaMKII levels in the brain of rats through Western blot and immunohistochemical analysis. We found that both propofol and ketamine could depress p-CaMKII, not T-CaMKII, In addition, the results showed that propofol-induced decrease in p-CaMKII was only anesthetic depth dependent, whereas ketamine could induce both dosage and anesthetic depth-dependent inhibitions of p-CaMKII, but its time course delayed relative to the time course observed with propofol. The lack of a dose response for propofol and anesthetic action might be owing to the route of administration, that is, the poor and inconsistent absorption of propofol after intraperitoneal injection.
The delayed suppression of p-CaMKII by ketamine could be explained by its heterogeneous effects on cerebral metabolism in different regions of rat brain. 19 These results may suggest that both propofol and ketamine work with similar effects on p-CaMKII, and in both cases they correlate with anesthetic depth.
An important question is whether the individual differences in anesthetic depth can be identified. In veterinary and human anesthesia, several electroencephalographic parameters, such as bispectral analysis index, electroencephalogram (EEG), and auditory-evoked potentials (AEPs) were applied to evaluate the anesthetic depth. However, there are conflicting data regarding the value of the EEG and AEPs as measures of anesthetic depth. Studies showed poor relation between EEG activity and clinical signs both in humans [20] [21] [22] and rats, 23, 24 and even inverse relationship between anesthetic depth and facilitation of AEP responses. [25] [26] [27] Instead of EEG and AEPs, a range of nociceptive stimuli and their related clinical responses might be used to evaluate anesthetic depth. 28 In this study, we also found both propofol and ketamine induced anesthetic depth-dependent inhibition of p-CaMKII in hippocampus and cortex of rats. Although the exact mechanism of anesthesia in the brain is unclear, the most likely explanation is that it may be owing to the inhibition of the excitatory postsynaptic potential of the cerebral cortex. 29 As the main ingredient of postsynaptic density (PSD), CaMKII activation via the increase of intracellular Ca 2+ or its autophosphorylation at threonine 286 are involved in the modulation of neuronal excitability and neurotransmission, and the molecular basis of long-term potential (LTP), learning, and memory. 1, 30 Mice lacking CaMKII or with mutation of the autophosphorylation site from threonine 286 to alanine exhibited severe deficits in LTP and spatial learning. 31, 32 CaMKII autophosphorylation results in switching of the kinase to a Ca 2+ /CaM-independent state and its translocation to the PSD. PSD-associated CaMKII in turn phosphorylates ionotropic glutamate receptors (NMDA and a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors), thus providing a mechanism for increased synaptic signaling during LTP. Furthermore, phosphorylation of the GluR1 subunit of the a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor by the activated CaMKII leads to an enhanced receptor channel conductance, 33 which plays a major role in mediating the postsynaptic mechanism of LTP. Propofol 34, 35 and ketamine 36 impair learning and memory on the basis of its ability to block LTP in the hippocampus in animal models. Animal studies suggest that NMDA receptor antagonism impairs the acquisition of information by disrupting LTP in the hippocampus. 37 CaMKII is an essential player in the NMDA receptormediated increase in conductance at glutamatergic synapses. 38 Propofol is a partial inhibitor of NMDA receptors, and inhibition of L-type Ca 2+ channels by propofol coupled with GABAergic effects could account for the block of NMDA receptor-independent forms of LTP. 35 Our findings of a strong link between individual variability in levels of p-CaMKII and anesthetic depth may suggest that propofol and ketamine inhibit CaMKII phosphorylation through NMDA receptors or VDCCs, but it needs further investigations.
In conclusion, the present study described a picture of the effects of propofol and ketamine on p-CaMKII in rat hippocampus and frontal cortex for the first time. Furthermore, the present data offer a unique finding that the decreased p-CaMKII levels were in accordance with anesthetic depths achieved by propofol and ketamine, which may be related to the effects of propofol and ketamine on CNS function and their clinical effect. However, the precise pharmacologic mechanisms remain undetermined. Further studies are needed to clarify the relationship between these functions and ketamine or propofol-induced changes in p-CaMKII.
